Connect with us

News

NHS plans to eliminate cervical cancer in England by 2040

The NHS aims to set out plans to improve access to HPV vaccination appointments and maximise cervical screening uptake

Published

on

The NHS has pledged to eliminate cervical cancer in England by 2040, in a move that could save thousands of lives.

Speaking at NHS Providers’ annual conference, NHS chief executive Amanda Pritchard has outlined how the health service can achieve the goal for elimination by making it as easy as possible for people to get the lifesaving HPV vaccination and increasing cervical screening uptake.

England is among the first countries in the world to set this elimination ambition within the next two decades. The World Health Organisation considers cervical cancer to be eliminated as a public health problem when there is an incidence rate lower than four per 100,000 women.

As part of new plans to put the NHS one step closer to eliminating the HPV virus, which causes up to 99 per cent of cervical cancers, Pritchard said health professionals will be supported to identify those who most need the vaccine.

The NHS will also set out plans to improve access to online vaccination appointments nationally, with millions more people able to view their full vaccination record and book vaccines on the NHS App over the coming months.

Vaccinations, Pritchard said, will become part of a “one-stop shop”, with NHS staff set to expand the offer of blood pressure tests and other health checks and advice, alongside routine vaccinations.

The HPV vaccine prevents invasive strains of the virus, known to cause almost all cervical cancers, as well as some mouth and throat cancers. It is given to both girls and boys in secondary school to protect them against catching the HPV infection and developing into pre-cancerous and cancer cells.

To eliminate cervical cancer by 2040, the NHS needs to ensure as many people as possible are being vaccinated against HPV, while also coming forward for cervical screening.

Pritchard said: “It is truly momentous to be able to set out such an important, life-saving ambition. To eliminate cervical cancer would be an incredible achievement and through a combination of our HPV vaccination programme and our highly-effective cervical screening programme, it could become a reality in in the next two decades.

“Vaccination and screening are the key tools which mean we are one step closer to achieving this and the NHS is already making it easier than ever before for people to protect themselves and their families – whether it’s through community outreach in areas of lower uptake or expanding the NHS app so that everyone has their vaccine history and booking options in the palm of their hand.

“As ever, the public can play their part by coming forward for their vaccines and screening appointments when invited – to achieve our goal of eliminating cervical cancer, we need as many people as possible to take up the offer, so please don’t delay – it could save your life.”

Around 2,700 women are diagnosed with cervical cancer in England each year, but the NHS screening programme helps save around 5,000 lives each year.

NHS screening helps prevent cervical cancer by using a test to check for high-risk HPV which may cause abnormal cells to develop in the cervix. These abnormal cells can, over time, turn into cancer if left untreated.

The NHS is inviting more people than ever before for cervical screening, while self-sampling will be trialled to determine if it could be introduced as part of national screening.

Steve Russell, chief delivery officer and national director for vaccinations and screening for NHS England, said: “Vaccination and screening are some of the most powerful tools we have for preventing disease and for keeping people from becoming unwell.

“We have learnt invaluable lessons from the pandemic, with our hugely successful Covid-19 vaccine programme saving thousands of lives, and our vision for the future of vaccination draws on those learnings, with plans to educate millions more people on the importance of vaccination, while making it easier than ever before to access vaccines online.”

Through routine and post-pandemic catch-up programmes, by school age year 10, 86 per cent of girls and 81 per cent of boys received one dose of the HPV vaccine, with studies suggesting the vaccine programme has prevented around 450 cancers and 17,200 pre-cancers.

Following the latest advice from the Joint Committee on Vaccination and Immunisation (JCVI), the NHS recently updated its HPV vaccination programme to single dose instead of two doses for under 25s.

This move will make it more convenient for young people to ensure they are protected and up to date with their vaccinations.

Professor Peter Johnson, national clinical director for cancer at NHS England, said: “It’s tremendous news that we are on track to eliminate cervical cancer by 2040 in this country. But alongside the success of the HPV vaccine for both boys and girls, regular cervical screenings for women are still essential to stop the development of cancerous cells in their tracks.

“A third of women do not take up the offer of cervical screening when invited, which is still a big risk for our plans.

“Cervical cancer often causes no symptoms during the early stages of the disease, so it is especially important that people attend their tests when in invited by the NHS and that those who are eligible get vaccinated against HPV.”

Cancer Research UK’s head of health and patient information, Dr Julie Sharp, added: “We support NHS England’s target and pledge to save even more lives from cervical cancer. Combined with screening, HPV vaccination could reduce cervical cancer to the point where almost no one develops it.

“To ensure everyone has equal access to these life-saving programmes, there must be targeted action to increase HPV vaccination coverage and reduce barriers to cervical screening.

“This ambition will only be possible if the vaccination and screening programmes are backed by sufficient resource and modern IT infrastructure.”

Martin Hunt, CEO of Jo’s Cervical Cancer Trust said: “We’re really pleased that NHS England is pledging to eliminate cervical cancer by 2040.

“The HPV vaccination programme is incredibly successful and has already led to an 87 per cent decrease in cervical cancer incidence in women in their 20s.”

He added: “It’s fantastic to see renewed efforts to make sure that everyone has the opportunity to receive the jab and reduce their risk of cervical cancer. By improving the uptake of both cervical screening and HPV vaccines, we can make cervical cancer a thing of the past.”

To receive the Femtech World newsletter, sign up here.

Fertility

GLP-1 drugs do not increase pregnancy risks, study finds

Published

on

GLP-1 drugs taken before conception were not linked to higher pregnancy risks in new research, which suggested they may even offer some protection.

Women of reproductive age are increasingly prescribed GLP-1 drugs for weight-management support, but the risks and benefits of using them before pregnancy remain poorly understood.

The findings support continuing the use of GLP-1 medicines in women with metabolic risk factors who are considering pregnancy, said Cara Dolin, a maternal-fetal medicine specialist and co-author of the research, which was presented at the Society of Maternal-Fetal Medicine pregnancy meeting in February 2026.

“While there’s more research to be done, this data provides some reassurance that it is not harmful to be taking a GLP-1 if you’re planning a pregnancy, and that having done so may in fact benefit you by optimising your preconception metabolic health.”

The researchers examined electronic medical records for patients with a pre-pregnancy BMI of more than 30 who delivered at more than 20 weeks’ gestation. The data were reviewed for two studies: one assessed the link between pre-pregnancy GLP-1 use and the risk of gestational diabetes, while the second looked at the risk of severe maternal morbidity in patients with obesity.

Women with obesity, diabetes, cardiovascular disease and other cardiometabolic disorders have a higher risk of pregnancy complications including preeclampsia, gestational diabetes, stillbirth, caesarean section and other outcomes. While GLP-1 medicines can help manage these conditions, they are contraindicated during pregnancy, and women are typically advised to stop the medication two months before trying to conceive.

However, stopping the drugs can often lead to rebound weight gain or worsening metabolic health. A 2025 study suggested this rebound worsened some pregnancy outcomes, but the risks and benefits are still poorly understood, Dolin said.

“There is a lot we just don’t know, which is why we wanted to look at our experience here with our Cleveland Clinic patients and see whether taking GLP-1 drugs before pregnancy was causing harm or if it was beneficial and helping patients have healthier pregnancies.”

Researchers analysed data for more than 8,000 women who had obesity but did not have diabetes before they became pregnant. They compared outcomes for 208 women who had been prescribed GLP-1 receptor agonists before pregnancy with those who had not been prescribed the medication.

Women in the GLP-1 group had more risk factors heading into pregnancy. They tended to be older and have a higher body mass index, higher rates of bariatric surgery and chronic high blood pressure, and present earlier for prenatal care.

However, outcomes for the two groups were similar. Researchers found that the GLP-1 group did not have higher rates of gestational diabetes, severe maternal morbidity or other adverse maternal outcomes, suggesting that the medication may have helped mitigate elevated risk factors.

“I think this is a really important signal, and it may reflect that these patients were able to optimise their metabolic health prior to conception.”

“It shows there’s potential to use these drugs in a more targeted way with patients who are planning a pregnancy and have these different comorbidities and obesity.”

While the findings suggest that using GLP-1 drugs before pregnancy may be beneficial in women with metabolic risk factors, having a plan to stop the medicines before conception is essential, Dolin noted. In some cases, patients may be moved to an alternative medication that is safe for pregnancy and can be used to help manage their metabolic health during pregnancy.

Providers with patients who are taking GLP-1 medicines and planning a pregnancy should consider referral to a maternal-fetal medicine specialist for pre-pregnancy counselling.

“We can have a nuanced conversation with the patient about taking the medication, what the benefits are, what the potential risks are, and help them formulate a plan to transition off the medication once they’re ready to start trying to conceive,” she said.

Continue Reading

Cancer

New scan could speed up endometriosis diagnosis

Published

on

Obesity may be a key driver of rising rates of 11 cancers in adults under 50, a study has found.

The 11 cancers were thyroid, multiple myeloma, liver, kidney, gallbladder, colorectal, pancreatic, endometrial, oral, breast and ovarian cancers.

All except oral cancer are known to be linked to excess weight, with researchers saying raised insulin levels and inflammation may play a part.

The findings come from researchers at the Institute of Cancer Research, London and Imperial College London, who analysed national cancer registry data for England from 2001 to 2019.

In England, around 31,000 cancers were diagnosed in people aged 20 to 49 in 2023, equal to roughly one in every 1,000 people. This compares with 244,000 cases in the 50 to 79 age group, where the rate is around one in 100.

Concerns have been growing in recent years over rising rates of cancers such as bowel and ovarian in younger adults.

Among the younger group, breast cancer was the most common, with 8,500 cases, followed by bowel cancer at 3,000 and melanoma skin cancer with 2,800 diagnoses.

For nine of the 11 cancers identified, rates are rising in younger adults but also increasing in older adults, who are much more likely to develop the disease. Bowel and ovarian cancer were the exceptions, rising only in younger age groups.

The researchers found that bowel cancer rates in younger women linked to BMI rose faster, from 0.9 to 1.6 per 100,000 people, than those not linked to BMI, which rose from 6.4 to 9.6 per 100,000 people. Similar patterns were recorded for men.

However, the authors noted that the overall number of cases of BMI-linked bowel cancer in younger women remained lower than those not linked to BMI, suggesting other factors must be contributing to the increase.

Several suspected contributors, including ultra-processed foods, antibiotic use and air pollution, have been proposed in recent years. However, many of these factors have also shown stable or declining trends in the UK, the team said.

Despite the rise in several cancer rates among younger adults over the past two decades, most established risk factors, including smoking, alcohol consumption, red or processed meat intake, low fibre diets and lack of exercise, remained stable or even declined in the period leading up to diagnosis.

This suggests these traditional risk factors are unlikely to account for much of the increase in cancer cases.

By contrast, overweight and obesity, which have increased steadily since 1995, could be key factors in the rise in cases. The team suggested that between 2001 and 2019, around 20 per cent of the increase in bowel cancer was explained by increases in BMI over that period.

However, the researchers said rises in BMI alone are not enough to explain the overall increase in cancer among younger adults in England and that there are likely to be other causes.

Data also suggest around 15 per cent of bowel cancer in younger people could be linked to being overweight or obese, with around 40 to 50 per cent in total linked to the combined effect of known risk factors such as obesity, lack of exercise, alcohol and smoking.

Montse García-Closas, professor at the ICR, said more research was needed, but “we cannot wait to act”.

She told a media briefing: “Our main conclusion is that although BMI is our best clue, much of the increase still remains unexplained, and we’ve done some additional analysis that show that most likely what’s missing is not just a single cause unexplained, but it’s likely a combination of multiple factors that act together.”

Amy Berrington, professor at the ICR, said: “Although rates have been increasing, cancer in young people is still a rare disease.”

Marc Gunter, professor at Imperial, said obesity was a known risk factor for around 19 different cancers.

He added: “For some of these cancers, including colorectal (bowel) cancer, we think this could be partly caused by higher levels of hormones such as insulin, which is often elevated in people with obesity, as well as inflammation.

“We know people with obesity have higher levels of insulin, and insulin is a growth factor and has been linked to cancer.

“In a recent study, we actually found that insulin in particular might be playing a role in early onset colorectal (bowel) cancer, and this is actually an area of very active research at the moment.”

The researchers called for large, long-term studies to identify all the biological and environmental factors that could explain rising cancer rates in young adults.

García-Closas added: “Tackling obesity across all ages, particularly in children and young people, through stronger public health policies and wider access to effective interventions, could slow the rise in cancer and prevent many cancers and must become a national priority.”

Michelle Mitchell, Cancer Research UK’s chief executive, said: “Globally, and in the UK, we’re seeing a small increase in cancer rates in adults under 50.

“The picture is complex and we need more research to understand what’s driving the trend, but this study helps to fill in some gaps.

“Overweight and obesity doesn’t explain the rise in full though. Improvements in detection are likely to also be playing a part, meaning that more people are being diagnosed at a younger age.

“Preventing cancer cases must be a priority for the UK government. Smoking remains a leading cause of cancer in adults under 50, which is why the Tobacco and Vapes Bill receiving royal assent this week is such a historic moment.

“Measures to restrict the advertising and promotion of junk food, introducing mandatory reporting and targets on healthy food sales, and making nutritious food more accessible to everyone would all help people keep a healthy weight.”

Continue Reading

Diagnosis

WHO launches AI tool for reproductive health information

Published

on

The World Health Organization (WHO) has launched an AI tool in beta to help policymakers, experts and healthcare professionals access sexual and reproductive health information faster.

Called ChatHRP, the tool was created by WHO’s Human Reproduction Programme and draws only on verified research and guidance collected by HRP and WHO.

It uses natural language processing and retrieval-augmented generation to produce referenced content and cut the time spent searching through documents across different platforms and databases.

WHO said ChatHRP also has multilingual capabilities and low-bandwidth functionality to support use in a wide range of settings.

The beta-testing phase is aimed at a broad professional audience, including policymakers, healthcare workers, researchers and civil society groups.

WHO said the tool can help users quickly access up-to-date evidence, find sources for academic work and verify information on sexual and reproductive health and rights.

Examples of questions it can answer include the latest violence against women data in Oceania for women aged 15 to 49, recommendations on managing diabetes during pregnancy, and whether PrEP and contraception can be used at the same time. PrEP is medicine used to reduce the risk of getting HIV.

WHO added that the system will be updated regularly as new HRP materials are published and includes a feedback loop so users can flag gaps in the information provided.

The launch comes amid wider concern about misinformation in sexual and reproductive health.

A 2025 scoping review found that misinformation in digital spaces is a systemic issue that can undermine human rights, reinforce discriminatory social norms and exclude marginalised voices.

The review also said misinformation can affect health systems by shaping provider knowledge and practice, disrupting service delivery and creating barriers to equitable care.

WHO said ChatHRP is intended to give users streamlined access to reliable information as a counter to “algorithms, opinions, or misinformation”.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.